AJTR Copyright © 2009-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711
Am J Transl Res 2010;2(1):1-18

Review Article
From bench to bedside: the growing use of translational research in
cancer medicine

Erin M. Goldblatt, Wen-Hwa Lee

Department of Biological Chemistry, School of Medicine, University of California, Irvine. Irvine CA 92697, USA

Received July 2, 2009; accepted July 16, 2009; available online January 1, 2010

Abstract: Cancer is responsible for one in eight deaths worldwide, with more than twelve million new cases
diagnosed yearly. A large percentage of patients die after developing cancer despite aggressive treatment,
indicating a need for new approaches to cancer therapy. The push for development of novel diagnostic and
therapeutic agents has allowed translational cancer research to flourish. Genomic and proteomic technologies
have generated an enormous amount of information critical to expanding our understanding of cancer biology.
New research on the differences between normal and malignant cell biology has paved the way for the
development of drugs targeted to specific biological molecules, potentially increasing antitumor efficacy while
minimizing the toxicity to the patient that is seen with conventional therapeutics. Current targets in include
regulators of cell cycle, angiogenesis, apoptosis, DNA repair, and growth factors and their receptors.
Collaboration among researchers, clinicians, and pharmaceutical companies is vital to conducting clinical trials
to translate laboratory findings into clinically applicable therapeutics. In this review, we discuss current
therapeutic approaches and present an introduction to a wide range of topics undergoing investigation in an effort
to highlight the importance of translational research in the development of clinically relevant therapeutic
strategies. (AJTR907001).

Key words: Translational medicine, translational research, from bench to bedside, individualized therapy, cancer

Full Text  PDF  

Address all correspondence to:
Wen-Hwa Lee, PhD
Department of Biological Chemistry
School of Medicine
University of California at Irvine
Irvine, CA 92697, USA
E-mail:
whlee@uci.edu